Functional genetics of APR-246 rescuable TP53 mutants

被引：0
|
作者：
Saunders, Anais
Tong, Caili
Karnezis, Anthony N.
Leiserowitz, Gary S.
Chein, Jeremy R.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
631
引用
收藏
页数：2
相关论文
共 50 条
  • [31] TP53 Mutants in the Tower of Babel of Cancer Progression
    Bisio, Alessandra
    Ciribilli, Yari
    Fronza, Gilberto
    Inga, Alberto
    Monti, Paola
    HUMAN MUTATION, 2014, 35 (06) : 689 - 701
  • [32] Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
    Xiaolei Zhou
    Gema Sanz Santos
    Yue Zhan
    Mariana M. S. Oliveira
    Shiva Rezaei
    Madhurendra Singh
    Sylvain Peuget
    Lisa S. Westerberg
    John Inge Johnsen
    Galina Selivanova
    British Journal of Cancer, 2022, 127 : 2060 - 2071
  • [33] Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
    Zhou, Xiaolei
    Santos, Gema Sanz
    Zhan, Yue
    Oliveira, Mariana M. S.
    Rezaei, Shiva
    Singh, Madhurendra
    Peuget, Sylvain
    Westerberg, Lisa S.
    Johnsen, John Inge
    Selivanova, Galina
    BRITISH JOURNAL OF CANCER, 2022, 127 (11) : 2060 - 2071
  • [34] Strong synergistic effects with APR-246 and cisplatin in p53-mutant lung cancer cells
    Mohell, Nina
    Fransson, Asa
    Alfredsson, Jessica
    von Euler, Mikael
    Bjorklund, Ulf
    Abrahmsen, Lars
    CANCER RESEARCH, 2015, 75
  • [35] Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Goldberg, Aaron D.
    Winer, Eric S.
    Altman, Jessica K.
    Fathi, Amir T.
    Odenike, Olatoyosi
    Roboz, Gail J.
    Gallacher, Phillip
    Wennborg, Anders
    Hickman, Denice Kaylor
    Attar, Eyal C.
    Sallman, David A.
    BLOOD, 2021, 138
  • [36] Phase 1b/2 Combination Study of APR-246 and Azacitidine in Patients With TP53-Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
  • [37] Impact of combined MRP1 inhibition and mutant p53 targeting compound APR-246
    Ceder, Anna Sophia
    Eriksson, Sofi E.
    Cheteh, Emarndeena Haji
    Bykov, Vladimir J. N.
    Abrahmsen, Lars
    Wiman, Klas G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
    Lena Haffo
    Jun Lu
    Vladimir J. N. Bykov
    Sebastin S. Martin
    Xiaoyuan Ren
    Lucia Coppo
    Klas G. Wiman
    Arne Holmgren
    Scientific Reports, 8
  • [39] Disruption of SLFN5 enhances vulnerability to APR-246, a mutant p53 reactivator in glioblastoma
    Perez, Ricardo E.
    Eckerdt, Frank
    Platanias, Leonidas C.
    CANCER RESEARCH, 2024, 84 (05)
  • [40] Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
    Sallman, David A.
    Komrokji, Rami S.
    De Zern, Amy E.
    Sebert, Marie
    Garcia-Manero, Guillermo
    Rahme, Ramy
    Steensma, David P.
    Che, Jacqueline Lehmann
    Roboz, Gail J.
    Madelaine, Isabelle
    Sekeres, Mikkael A.
    Peterlin, Pierre
    Sweet, Kendra
    Rauzy, Odile Beyne
    Kuykendall, Andrew T.
    Recher, Christian
    McLemore, Amy F.
    Stamatoullas, Aspasia
    Zhang, Ling
    Willems, Lise
    Mo, Qianxing
    Raffoux, Emmanuel
    Nardelli, Lisa
    Berthon, Celine
    Al Ali, Najla
    Quesnel, Bruno
    Padron, Eric
    Korbel, Greg
    Attar, Eyal C.
    Kantarjian, Hagop
    List, Alan F.
    Ades, Lionel
    Lancet, Jeffrey E.
    Fenaux, Pierre
    Cluzeau, Thomas
    BLOOD, 2021, 138
12345